Is Interferon Effective and Safe for Relapsing-Remitting Multiple Sclerosis?

Publisher： Karger

E-ISSN： 1423-0208|21|6|310-

ISSN： 0251-5350

Source： Neuroepidemiology, Vol.21, Iss.6, 2002-11, pp. : 310-

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

By  

European Neurology, Vol. 59, Iss. 3-4, 2007-11 ,pp. : 131-135

Karger

Access to resources Recommend Favorite

Switching to Second-Line Therapies in Interferon-Beta-Treated Relapsing-Remitting Multiple Sclerosis Patients

By  

European Neurology, Vol. 61, Iss. 3, 2009-01 ,pp. : 177-182

Karger

Access to resources Recommend Favorite

Azathioprine and Interferon β1a in Relapsing-Remitting Multiple Sclerosis Patients: Increasing Efficacy of Combined Treatment

By  

European Neurology, Vol. 51, Iss. 1, 2004-01 ,pp. : 15-20

Karger

Access to resources Recommend Favorite

CXCL11 (Interferon-Inducible T-Cell Alpha Chemoattractant) and Interleukin-18 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Methylprednisolone

By  

European Neurology, Vol. 58, Iss. 4, 2007-09 ,pp. : 228-232

Karger

Access to resources Recommend Favorite

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait

By  

Medical Principles and Practice, Vol. 22, Iss. 5, 2013-06 ,pp. : 495-499

Karger

Access to resources Recommend Favorite